Areas of expertise
Cell Therapy Quality Assessment
Improve efficacy, predict patient response and longevity the treatment
Patient Safety
Anticipate and reduce the toxicity of Cell Therapy
Reduce Cell Therapy R&D costs
Accelerate cell manufacturing cycles by implementing QC methods derived from single-cell analysis and ScaiVision AI-platform
Best-in-class Plan
1.
Get in touch
Let us address your most common challenges
2.
Project setup and data acquisition
We will customise our services to your needs
3.
Data analysis & result delivery
We deliver
We are leveraging single-cell technologies and our best-in-class AI Platform ScaiVision to monitor “desirable functional states”, molecular profiles, and cellular populations in Cell Therapy to enhance Efficacy and reduce Toxicity.
We are set to improve clinical outcomes and reduce drug development life cycles by leveraging single-cell technologies and our proprietary AI platform ScaiVision.
Prof. Dr Michael Mueller
Leading Clinician in Women’s Health & Scientific Advisor
“Our current collaboration with Scailyte in the field of women’s health is a truly innovative approach. We are integrating cutting edge technologies to develop biomarkers that will be the basis for impactful diagnostic solutions.”
Pascal Koenig
Entrepreneur & Chairman of the Board of Directors
“As the co-founder and former CEO of Ava Women, I have experienced the power that big datasets have on the healthcare industry. Scailyte’s mission, proven technology and strong expertise have convinced me to join the team. I am delighted to contribute and assist in bringing Scailyte’s solution to patients around the world.”
Dominique Mégret
Scailyte Board of Directors & Head Swisscom Ventures
“Precision medicine is poised to become a standard in the future, however today it is facing a major obstacle: a data problem. The robust analytical engine of Scailyte makes it an enabler of precision medicine. We decided to support the company because we believe in the technology, as well as in the talented team behind it.”
Prof. Woong-Yang Park
Founder and CEO of Geninus
“Geninus aims to implement single-cell genome analysis techniques to facilitate personalized patient care. Scailyte’s machine learning model will add value to the single-cell
gene expression profile of patients. Through collaboration with Scailyte, we hope to provide prognostic methods for immunotherapy response in precision medicine clinics.”
Recent News
VACANCY: Regulatory Affairs / Quality Management Specialist
We are currently developing a first-in-class in vitro diagnostic tool for Endometriosis aiming at cu
Recent News
Scailyte Webinar - Why single-cell technologies are vital for Endometriosis research
Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of th
Recent News
Single-Cell Discovery Grant in Oncology and Immunology
Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo
Recent News
Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies
Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution
Recent News
Scailyte Quarterly Update, June 2021
Quarterly update on Scailyte's progress towards its mission to save millions of lives.
Recent News
Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors
Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich
Recent News
Recent News
Scailyte Quarterly Update, April 2021
Quarterly update on Scailyte's progress towards its mission to save millions of lives.
Recent News
VACANCY: Regulatory Affairs / Quality Management Specialist
We are currently developing a first-in-class in vitro diagnostic tool for Endometriosis aiming at cu
Scailyte Webinar - Why single-cell technologies are vital for Endometriosis research
Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of th
Recent News
Single-Cell Discovery Grant in Oncology and Immunology
Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo
Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies
Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution
Recent News
Scailyte Quarterly Update, June 2021
Quarterly update on Scailyte's progress towards its mission to save millions of lives.
Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors
Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich
Recent News
Scailyte Quarterly Update, April 2021
Quarterly update on Scailyte's progress towards its mission to save millions of lives.